Compare Ascendis Pharma A/S (ASND) vs Verizon Communications Inc (VZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Verizon Communications Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Verizon Communications Inc trades at $42.35 (market cap $175.87B). The key difference: Verizon Communications Inc is far larger — about 9.9× Ascendis Pharma A/S's market cap, and Verizon Communications Inc pays a 6.72% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VZ | |
|---|---|---|
Market Cap | $17.74B | $175.87B |
Sector | Health | Media |
52-Week High | $277.18 | $51.38 |
52-Week Low | $163.32 | $38.40 |
Enterprise Value | $18.11B | $363.38B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Verizon (VZ) trades at $42.12, down 0.28% today, with a bearish technical signal but strong fundamentals including a P/E of 10.27 and consistent earnings beats. Recent news highlights include a new BMW connectivity partnership and inclusion in high-yield dividend stock lists. Cash flow improved significantly in 2025 with net cash flow of $14.9 billion, though long-term debt remains elevated at $121.38 billion.
Outlook: VZ offers value with a 6.7% dividend yield and analyst consensus price target of $48.17 (14% upside). Risks include competitive pressure from SpaceX's Starlink and high debt load. The stock is a buy for income investors seeking stability, but growth may be limited by industry saturation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
